Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of suvorexant to prevent delirium in high-risk hospitalized Japanese older adults
jRCT2031200149Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delirium comparing Suvorexant 15 mg with Placebo (2 arms). Primary endpoints: Percentage of participants with delirium (DSM-5), Number of participants with one or more adverse events and 1 more. Started Oct 2020; status: completed.
02
Drugs
suvorexant
03
Conditions
delirium
Beyond the preview
Go deeper on jRCT2031200149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200149.